广谱抗HIV-1中和抗体中和敏感性筛查检测的评估与实际应用经验
研究评估了经CLIA验证的PhenoSense单克隆抗体检测在多个近期广谱中和抗体(bnAb)临床试验中的应用表现。该检测在不同样本类型间重现性好、结果一致,但与已发表的实验室评估相关,基线bnAb敏感性并不能一致预测持久病毒抑制,检测成功率与处理时间数据来自4项近期临床研究。
要点
- PhenoSense检测在血浆和纵向外周血单个核细胞样本中重现性好、样本类型间一致。
- 基线bnAb敏感性不能一致预测持久病毒抑制。
- 检测的后勤与操作要求可影响临床试验的及时开展。
核心结论
- PhenoSense单克隆抗体检测可在相关样本类型中提供可重现的bnAb敏感性测量,但不能一致预测病毒抑制。
- 检测的后勤与操作要求可影响临床试验的及时开展,这些结果可为开发中的bnAb研究提供参考。
研究设计与样本
- 评估经CLIA验证的PhenoSense单克隆抗体检测(Labcorp-Monogram Biosciences),该检测已在多个近期bnAb临床试验中前瞻性和回顾性使用。
主要发现
- 在来自近期临床试验的血浆和纵向外周血单个核细胞样本(分别于抗逆转录病毒治疗前和治疗期间采集)中,PhenoSense检测在临床开发中bnAb的敏感性测量方面表现出稳健的重现性、样本类型间一致性和预期范围。
- 回顾性应用于3项近期研究的基线样本时,PhenoSense检测与已发表的实验室研究评估相关,但基线bnAb敏感性不能一致预测持久病毒抑制。
- 在4项近期临床研究中评估检测可行性,提供了检测成功率和处理时间的估计值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Development of a screening assay for the clinical use of broadly neutralizing antibodies (bnAbs) is a priority for HIV therapy and cure initiatives. METHODS: We assessed the PhenoSense Monoclonal Antibody Assay (Labcorp-Monogram Biosciences), which is Clinical Laboratory Improvement Amendments (CLIA) validated and has been used prospectively and retrospectively in multiple recent bnAb clinical trials. RESULTS: When performed on plasma and longitudinal peripheral blood mononuclear cell samples (before and during antiretroviral therapy, respectively), as sourced from a recent clinical trial, the PhenoSense assay produced robust reproducibility, concordance across sample types, and expected ranges in the susceptibility measures of bnAbs in clinical development. When applied retrospectively to baseline samples from 3 recent studies, the PhenoSense assay correlated with published laboratory-based study evaluations, but baseline bnAb susceptibility was not consistently predictive of durable virus suppression. Assessment of assay feasibility in 4 recent clinical studies provides estimates of assay success rate and processing time. CONCLUSIONS: The PhenoSense Monoclonal Antibody Assay provides reproducible bnAb susceptibility measurements across relevant sample types yet is not consistently predictive of virus suppression. Logistical and operational assay requirements can affect timely clinical trial conduct. These results inform bnAb studies in development.
引用
- Pahus MH, Zheng Y, Olefsky M, et al. Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti-HIV-1 Antibodies. J Infect Dis. 2025. PMID: 39441137. doi:10.1093/infdis/jiae486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。